BioCorRx Inc. (BICX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues, net | 178,238 | 134,899 | - | 4,045 |
| Depreciation and amortization | - | - | 6,714 | - |
| Selling, general and administrative | 1,223,321 | 886,083 | 1,192,869 | 830,321 |
| Research and development | 296,860 | 161,919 | 460,138 | 536,362 |
| Depreciation and amortization | 71,977 | 24,843 | - | 6,714 |
| Cost of implants and other costs | - | - | - | - |
| Total operating expenses | 1,592,158 | 1,072,845 | 1,659,721 | 1,373,397 |
| Loss from operations | -1,413,920 | -937,946 | -1,659,721 | -1,369,352 |
| Other miscellaneous income | - | - | 4,763 | 138,145 |
| Change in fair value of royalty liability | - | -2,611 | - | - |
| Other miscellaneous expense | - | 59,439 | - | - |
| Grant income | - | 413,979 | 572,777 | 518,667 |
| Change in fair value of upfront purchase price liability | - | -4,500 | - | - |
| Interest expense, net | 36,686 | 87,483 | 148,999 | 317,907 |
| Grant income | 154,270 | - | - | - |
| Loss on settlement of debt | -55,000 | -132,514 | -123,563 | - |
| Change in fair value of royalty liability | 33,935 | - | - | - |
| Other miscellaneous income | 104,890 | - | - | - |
| Interest expense - related parties | 164,371 | -160,128 | 158,267 | 203,549 |
| Change in fair value of upfront purchase price liability | -394 | - | - | - |
| Total other income (expense) | 36,644 | 86,182 | 146,711 | 135,356 |
| Loss before provision for income taxes | -1,377,276 | -851,764 | -1,513,010 | -1,233,996 |
| Income taxes | - | - | - | - |
| Net loss | -1,377,276 | -851,764 | -1,513,010 | - |
| Non-controlling interest | -143,858 | - | - | - |
| Non-controlling interest | - | 10,357 | 25,623 | 16,650 |
| Net loss attributable to biocorrx inc | -1,233,418 | -841,407 | -1,487,387 | -1,217,346 |
| Net loss attributable to biocorrx inc. | - | - | -1,487,387 | -1,217,346 |
| Basic & diluted average shares | - | - | - | 9,459,532 |
| Basic & diluted eps | - | - | -0.14 | -0.13 |
| Diluted average shares | - | 3,552,262 | - | - |
| Net loss per common share, basic and diluted | -0.07 | - | - | - |
| Weighted average number of common shares outstanding, basic and diluted | 17,011,680 | - | - | - |